title: Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
mesh_terms: D000069501:Abiraterone Acetate / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D059248:Chemoradiotherapy; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D064129:Prostatic Neoplasms, Castration-Resistant / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011788:Quality of Life; D011868:Radioisotopes / Q000008:administration & dosage; D011883:Radium / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D011868:Radioisotopes; D000069501:Abiraterone Acetate; C581106:radium Ra 223 dichloride; D011241:Prednisone; D011883:Radium